Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: Chronic lymphocytic leukemia (CLL) with 17p deletion typically progresses quickly and is refractory to most conventional therapies. However, some del(17p) patients do not progress for years, suggesting that del(17p) is not the only driving event in CLL progression. We hypothesize that other concomitant genetic abnormalities underlie the clinical heterogeneity of del(17p) CLL. Experimental Design: We profiled the somatic mutations and copy number alterations (CNA) in a large group of del(17p) CLLs as well as wild-type CLL and analyzed the genetic basis of their clinical heterogeneity. Results: We found that increased somatic mutation number associates with poor overall survival independent of 17p deletion (P = 0.003). TP53 mutation was present in 81% of del(17p) CLL, mostly clonal (82%), and clonal mutations with del(17p) exhibit shorter overall survival than subclonal mutations with del(17p) (P = 0.019). Del(17p) CLL has a unique driver mutation profile, including NOTCH1 (15%), RPS15 (12%), DDX3X (8%), and GPS2 (6%). We found that about half of del(17p) CLL cases have recurrent deletions at 3p, 4p, or 9p and that any of these deletions significantly predicts shorter overall survival. In addition, the number of CNAs, but not somatic mutations, predicts shorter time to treatment among patients untreated at sampling. Indolent del(17p) CLLs were characterized by absent or subclonal TP53 mutation and few CNAs, with no difference in somatic mutation number. Conclusions: We conclude that del(17p) has a unique genomic profile and that clonal TP53 mutations, 3p, 4p, or 9p deletions, and genomic complexity are associated with shorter overall survival. Clin Cancer Res; 23(3); 735–45. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461 · cited 2×
“Driver Genes in Del(17p) CLL To identify driver genes in del(17p) CLL, we ran the MutSigCV algorithm(30) on the 53 del(17p) CLL in our WES cohort.”
MethodSelf-citationGenomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999) · Blood · doi:10.1182/blood.v94.6.1848 · Cited by 2,783
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414 · cited 1×
“Chromothripsis has been previously reported in CLL, with a suggestion of association with del(17p) (43, 44).”
BackgroundEvolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379 · cited 1×
“A total of 134 of the 176 whole exomes were included in a previous study (25).”
BackgroundSelf-citation
Cited by
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 408
Chronic lymphocytic leukaemia: from genetics to treatment
Bosch, F., & Dalla-Favera, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0239-8 · Cited by 242
Kadri, S., Lee, J., Fitzpatrick, C., Galanina, N., Sukhanova, M., Venkataraman, G., Sharma, S., Long, B., Petras, K., Theissen, M., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003632 · Cited by 133
“However, a recent large study of 69 patients with del(17p) and CLL identified 3p, 4p, 8p, and 9p as recurrent events significantly associated with del(17p) but not del(18p).(41) Thus, the possibility remains that del(18p) does not happen by chance in the setting of ibrutinib treatment, and it may cooperate with TP53 i…”
Background
Metadata
- Authors
- Yu, L., Kim, H. T., Kasar, S. N., Benien, P., Du, W., Hoang, K., Aw, A., Tesar, B., Improgo, R., Fernandes, S. M., Radhakrishnan, S., Klitgaard, J. L., Lee, C., Getz, G., Setlur, S. R., & Brown, J. R.
- Venue
- Clinical Cancer Research
- Published
- 2017-01-31
- Volume
- 23
- Issue
- 3
- Pages
- 735-745
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2507865108
- Cited by
- 95
- References
- 5
- FWCI
- 7.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0594
- The paper
- Yu, L., Kim, H. T., Kasar, S. N., Benien, P., Du, W., Hoang, K., Aw, A., Tesar, B., Improgo, R., Fernandes, S. M., Radhakrishnan, S., Klitgaard, J. L., Lee, C., Getz, G., Setlur, S. R., & Brown, J. R. (2017). Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.